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Through extensive isolation of neutralizing mAbs against H3N2 influenza viruses representing the
in vivo repertoire in a human donor, we examined the relationships between antigenic drift of
influenza virus and protective antibodies generated in an infected individual. The majority of mAbs
isolated from a donor born in 1960 were divided into three major groups with distinct strain
specificity: 1968–1973, 1977–1993 and 1997–2003. In the present study, we developed a new
method that allowed us to comprehensively determine the location of epitopes recognized by
many mAbs. Original haemagglutinins (HAs) of several strains and chimaeric variants, in which
one of the seven sites (A, B1, B2, C1, C2, D or E) was replaced by some other strain-derived
sequence, were artificially expressed on the cell surface. The binding activity of mAbs to the HAs
was examined by flow cytometry. By using this method, we determined the location of epitopes
recognized by 98 different mAbs. Clones that neutralize the 1968–1973 strains bind to site B2/D,
A or A/B1. While sites C, E and B were recognized by clones that neutralized the 1977–1993
strains, the majority of these clones bind to site C. Clones that neutralize the 1997–2003 strains
bind to site B, A/B1, A/B2 or E/C2.
INTRODUCTION
Antibodies (Abs) play important roles in protection against
and recovery from influenza virus infection, and haemag-
glutinin (HA) is the main target for virus-neutralizing Abs
(Gerhard et al., 1997). Viruses with mutations in critical
residues of HA could preferentially survive under the
pressure of neutralizing Abs and cause future influenza
epidemics (Hay et al., 2001). Mutations mainly accumulate
in the five sites (A, B, C, D and E) on HA1 that should
include neutralizing epitopes (Underwood, 1982; Wiley
et al., 1981). To the best of our knowledge, however, very
little is known about the nature, range and specificity of
protective mAbs that are generated in infected individuals.
Since the outbreak of ‘Hong Kong’ influenza in 1968, the
H3N2 influenza viruses remain the most common cause of
flu. Therefore, in the present study, we examined the
neutralizing Abs against the H3 strains isolated between
1968 and 2004.
We attempted to reveal the relationships between the
location of epitopes recognized by neutralizing mAbs
against influenza viruses in a human donor and that of
mutations introduced in the epidemic strains. Previously
(Okada et al., 2010), we collected a large number of B
lymphocytes by apheresis from a donor born in 1960. Since
Supplementary materials describing the construction of plasmid DNAs
for cell-surface expression of HA and chimaeric HAs are available with
the online version of this paper.
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9, they probably represented 0.1–1% of his total B-cell
population. By using phage-display technology (Winter
et al., 1994), we constructed a large Ab library composed of
3610
10 clones. The library was screened against inacti-
vated virus particles of 12 different vaccine strains isolated
between 1968 and 2004. The clones that bound to the
antigens (Ags) were isolated, and mAbs that specifically
bound to H3-strain viruses were selected. Finally, their
binding activity to the 12 strains and neutralizing activity
were studied. The 1143 clones were analysed. The sequence
analysis revealed that they were composed of 153 unique
mAbs with different VH sequences. Of the 153 clones, 113
showed both binding activity and virus-neutralizing
activity, while the remaining 40 clones showed binding
activity but did not show neutralizing activity. The
majority of clones with neutralizing activity were anti-HA
Abs that could be divided into three major groups showing
distinct strain specificity: 1968–1973, 1977–1993 and 1997–
2003. In the present study, we analysed the location of the
epitopes recognized by these clones.
RESULTS
A new method for identifying the location of
epitopes recognized by mAbs with neutralizing
activity
Although epitopes could be identified by analyses of escape
mutants that can grow in the presence of neutralizing mAb
(Gerhard et al., 1981), this method is time-consuming and
labour-intensive, especially since we wanted to identify the
epitopes recognized by many mAbs. Therefore, we
developed a simpler method for epitope mapping that is
based on the analysis of chimaeras. After HA was artificially
expressed on the cell surface, the binding activity of
respective mAbs to HA was examined by flow cytometry
(FCM). Since the range of specificity of the majority of
clones was 1968–1973, 1977–1993 or 1997–2003 (Okada
et al., 2010), HAs of the following five strains were selected:
A/Aichi/2/68, A/Yamanashi/2/77, A/Fukuoka/C29/85, A/
Sydney/5/97 and A/Wyoming/3/2003. To identify the
epitope, several chimaeric HA variants for each strain were
constructed. We assumed that the epitopes would be
localized in one of the seven sites (A, B1, B2, C1, C2, D or
E), and we constructed chimaeric variants in which one of
the seven sites was replaced by some other strain-derived
sequence. Fig. 1(a) summarizes the amino acid sequences
of the original five HAs and their chimaeric variants, and
Fig. 1(b) shows the three-dimensional (3D) location of
amino acid residues changed in the chimaeric HA of the
Sydney/97 strain. In the case of the Aichi/68 strain, the
original HA and nine kinds of chimaeric HA were
constructed. To determine if the 3D structures of HAs
artificially expressed on the cell surface were properly
formed, the haemadsorption activity of the transfected cells
was examined. As shown in Fig. 2, several reticulocytes
were attached to cells expressing the original HA and nine
chimaeric HAs of the Aichi/68 strain. Essentially the same
results were obtained for the other four strain-derived HA-
transfected cells, with the exception of S97/50C1. These
results indicate that the receptor-binding sites of HAs
expressed on the cell surface were properly formed.
To further examine whether these constructs could
function as Ags, we performed pilot experiments with
three representative clones: F033-161, F032-072 and F008-
007. Fig. 3 shows the FCM profiles. Clone F033-161, which
binds and neutralizes the 1968–1973 strains, was tested for
its ability to bind the HAs of the Aichi/68 strains (Fig. 3a).
Clone F49, which binds to the epitope commonly present
on HAs of all the H3 strains, was used as a positive control
(Ueda et al., 1998). Clone F49 bound to the original HA-
transfected cells and the nine chimaeric HA-transfected
cells, suggesting that all of the HAs were expressed on the
cell surface. F033-161 did not bind to either A68/188B2- or
A68/219D-encoding DNA-transfected cells, but it did bind
to all of the other HA-encoding DNA-transfected cells.
These results suggest that F033-161 could not bind to HAs
encoded by A68/188B2 and A68/219D, although they were
present on the cell surface. We interpreted these results as
evidence showing that the epitope recognized by clone
F033-161 is located in site B2/D. Clone F032-072 was also
tested (Fig. 3b). Since it binds and neutralizes the 1977–
1993 strains, HAs of Yamanashi/77 and Fukuoka/85 were
used as binding targets. The results indicate that F032-072
does not bind to Y77/50C1, Y77/276C2, F85/50C1 or F85/
276C2; however, it does bind to all of the other HAs. We
concluded that clone F032-072 bound to site C1/C2.
Finally, clone F008-007 was examined (Fig. 3c). Since it
binds and neutralizes the 1997–2003 strains, HAs of
Sydney/97 and Wyoming/2003 were used as binding
targets. F49 did not react with S97/50C1; therefore, we
determined that this chimaeric HA molecule was not
properly expressed on the cell surface. F008-007 did not
bind to S97/155B1, S97/189B2 or S97/50C1. Since F008-
007 also did not bind to W03/156B1 or W03/189B2 but did
bind to all of the other HAs of the Sydney/97 and
Wyoming/2003 strains, we concluded that site B1/B2 may
contain the epitope recognized by this clone.
Based on the FCM results from the chimaeric HAs together
with the examination of their haemadsorption activity, we
concluded that the HA constructs of the five H3 strains,
with the exception of S97/50C1, could function as Ags
expressed on the cell surface and that the epitopes of these
Ags could be recognized by respective mAbs. Thus, we
termed this method EMAC (epitope mapping through
analysis of chimaeras).
Location of epitopes recognized by 98 mAbs that
neutralize H3N2 strains
We used the EMAC method to examine epitopes
recognized by mAbs with neutralizing activity. Ninety-
eight clones that had been classified into 27 groups (Okada
Epitope mapping of neutralizing Abs against H3N2 virus
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consisted of 11 clones (classified into groups 1–3) that
bound to the 1968–1973 strains. The second set consisted
of four clones (classified into groups 4 and 5) that bound
to the 1977–1999 strains and 54 clones (classified into
groups 6–19) that bound to the 1977–1993 strains. The
third set consisted of 14 clones (classified into groups 20
and 21) that bound to the 1993–2003 strains and 15 clones
(classified into groups 23–27 and 29) that bound to the
1997–2003 strains.
Fig. 2. Attachment of reticulocytes to the cells expressing wild-type (wt) or chimaeric HAs of Aichi/68 influenza strain. 293T
cells were transfected with plasmid containing wt or chimaeric HA genes of the Aichi/68 stain and incubated with guinea-pig
red blood cells. As a control, plasmid without the HA gene was used.
Fig. 1. Amino acid sequences of the seven antigenic sites in template and chimaeric HAs constructed in this study. (a) HAs of
five vaccine strains, Aichi/68 (Aic68), Yamanashi/77 (Yam77), Fukuoka/85 (Fuk85), Sydney/97 (Syd97), Wyoming/2003
(Wyo03), were used as starting materials. The deduced amino acid sequences showed discrepancies with the reported data
(Okada et al., 2010) at six residues, which are highlighted in grey. Since we used these plasmids for the expression of HA the
actual sequence determined is indicated in this figure. The name of the chimaeric HA and the amino acids that replaced the
original ones are indicated under the template HA. Bars indicate the same amino acids as those of Aichi/68. (b) Location of the
amino acids replaced in the chimaeric HA is indicated in the 3D structure of HA by using the examples of the Sydney/97 strain.
The amino acids that formed a receptor-binding site were marked in grey. The amino acids replaced in the chimaera were
marked as follows: site A, purple (121A), orange (131A) or red (142A); B1, blue; B2, light blue; C1, green; C2, light green;
D, pink; E, yellow.
J. Okada and others
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used to identify the epitopes of the clones in the first set.
The HAs of Yamanashi/77 and Fukuoka/85 and their
chimaeric HAs were used to identify the epitopes of the
clones in the second set. The HAs of Sydney/97 and
Wyoming/2003 and their chimaeric HAs were used to
identify the epitopes of the clones in the third set.
Numerous FCM analyses were systematically performed,
and the summary is shown in Fig. 4. The FCM results were
judged to be positive, indicating that the Ab bound to the
HA expressed on the cell surface, or negative, indicating
that the Ab did not bind to the HA.
All nine clones in group 1 did not bind to either A68/188B2
or A68/219D but did bind to the other seven chimaeric HAs.
Therefore, we concluded that they bound to site B2/D. Since
F035-015 of group 2 did not bind to A68/142A but did bind
to the other eight chimaeric HAs, including A68/121A and
A68/133A, we concluded that it bound to the C-terminal
side of site A. On the other hand, F033-038 in group 3 did
not bind to A68/133A, A68/142A or A68/154B1, but it did
bind to the other six chimaeric HAs. Therefore, we
concluded that it bound to site A/B1 (Fig. 4a).
Since clones in groups 4 and 5 bound to the HAs of 1977–
1999 strains, those of Sydney/97 were also used in the FCM
analysis in addition to Yamanashi/77 and Fukuoka/85.
F008-039 in group 4 did not bind to Y77/50C1, F85/50C1
or S97/275C2 but did bind to all of the other Yamanashi/
77, Fukuoka/85 and Sydney/97 chimaeric HAs tested.
Although it bound to Y77/276C2 and F85/276C2, site C2 of
these chimaeric HAs was changed from GTCSC (1977 and
1985 type) to GKCNS (1997 type), and F008-039 bound
not only to Yamanashi/77 and Fukuoka/85 HAs but also to
Sydney/97 HA. Thus, we concluded that F008-039 bound
to site C1/C2. While the results from the analysis of
Sydney/97 indicated that three clones of group 5 bound to
site E, they bound to all of the chimaeric HAs of
Yamanashi/77 and Fukuoka/85 including site E chimaera.
However, the clones of group 5 bound to the HAs of the
1977–1999 strains. Therefore, if they bound to site E, they
could bind to the HA with the sequence from the 78th to
83rd residues, GFQNEK (1977 and 1985 type) or GFQNKE
(1997 type), but could not bind to either VFQNET (1968
type) or GFQNKK (2003 type) (Fig. 1). The reason why
they bound to chimaeric HAs Y77/82E and F85/82E was
that site E sequence had been changed in both chimaeras
Fig. 3. FCM analyses of wt and chimaeric HAs
of five influenza strains. F49 is a mouse mAb
that recognizes an epitope commonly present
on HA of H3 subtype influenza viruses (Hay
et al., 2001). The Fab-PP form of Ab was used
for F033-161 (a), F032-072 (b) and F008-
007 (c).
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group 5 clones bind to site E (Fig. 4b).
All 14 clones in group 6 bound to site C1/C2. F020-334 in
group 7 was judged to bind to site C2 since the interaction
between F020-334 and F85/276C2 was negative. On the
other hand, the interaction between F020-334 and Y77/
276C2 was judged to be positive. However, the interaction
between F020-334 and site C1 and C2-chimaeric HA of
Yamanashi/77 and Fukuoka/85 strains was largely
decreased according to the raw data. Therefore, we
concluded that F020-334 bound to site C1/C2. F037-115
of group 12 bound to site B1, and six clones of group 19
recognized site E. The remaining clones, which were six
clones in groups 8–11 and 26 clones in groups 13–18, were
judged to bind to site C1/C2 (Fig. 4b).
The clones in the third set recognized a rather diverse set of
epitopes (Fig. 4c). The majority of clones in groups 20 and
25–27 were judged to bind site to B1/B2. F010-073 of
group 21 bound to site A/B1, and clones of group 23
bound to site E/C2. F004-136 of group 24 did not bind to
W03/142A or W03/189B2 but did bind to all five other
chimaeras. Therefore, we concluded that it recognized site
A/B2, although the results from Sydney/97 chimaeras were
rather marginal. The epitope recognized by the clones
belonging to 29 did not appear to be strictly fixed, but we
speculate that they might recognize site B2 and the
surrounding region.
Further validation of the EMAC method
Traditionally, an analysis of escape mutants is used to
identify epitopes. We compared the results obtained by the
EMAC method with the results from an analysis of escape
mutants, as indicated in Fig. 5. The epitope recognized by
F004-104 of group 20 and F004-136 of group 24 had been
revealed by the analysis of escape mutants (Okada et al.,
2010). Escape mutants were isolated by incubating A/
Wyoming/3/2003 viruses with IgG1 Ab. In the case of F004-
104, two types of variation, Y159N and D190E, were
identified, and the 159th and 190th residues were localized
in sites B1 and B2, respectively (Fig. 5a). According to the
EMAC method F004-104 did not react with either W03/
156B1 or W03/189B2 (Fig. 4c); thus, the epitope
recognized by the clone was mapped to site B1/B2. In the
escape mutants isolated in the presence of F004-136, the
mutation was identified to be K145Q. According to
the EMAC method, F004-136 did not react with either
W03/142A or W03/189B2 (Fig. 4c); thus, the epitope
recognized by the clone was mapped to site A/B2 (Fig. 5a).
As indicated in Fig. 5b, the amino acid residues that were
mutated in the escape mutants were located in the sites that
were changed in the chimaeras.
Haemagglutination inhibition (HI) activity
Since the HI activity has been routinely measured by many
researchers (Smith et al., 2004; Wang et al., 1986), we
examined the HI activity of the 98 mAbs whose epitopes
were analysed by the EMAC method (data not shown). The
results can be summarized as follows: (i) the majority of
the clones recognizing A and/or B site had strong HI
activity; (ii) the clones recognizing site E generally showed
HI activity but not strong activity; and (iii) the clones
recognizing site C did not show any HI activity. Since HI
activity is the ability of Ab to block the interaction between
HA and sialic acid, the regularity observed is reasonable.
DISCUSSION
In a previous paper (Okada et al., 2010), we reported the
strain specificity of clones that could represent the in vivo
repertoire of neutralizing mAbs against H3N2 influenza
viruses from a donor born in 1960. These clones could be
divided into three major groups showing distinct strain
specificity: 1968–1973, 1977–1993 and 1997–2003. In the
present study, we determined the location of epitopes
recognized by these mAbs. We developed a new method,
EMAC, that allowed us to comprehensively identify the
location of epitopes recognized by numerous clones. While
the EMAC method does not provide direct evidence
showing the location of an epitope, it is highly plausible
that the epitopes identified by this method are indeed
correct. All the locations identified were superimposed on
the 3D structure of the membrane-distal half of HA, which
includes five antigenic sites. Fig. 6 illustrates the sites
recognized by mAbs with neutralizing activity that were
isolated from the donor in June 2004. As indicated in this
figure, all five antigenic sites were immunogenic in the
donor.
A set of B cells producing Abs that can react with viruses
are generated by immunization through infection and/or
vaccination. Afterwards they will take various courses
under further stimulation with the Ags. Many B cells
disappear while others become memory cells. Since all of
the clones that were analysed in the present study were
highly mutated (see Table 2 in Okada et al., 2010), it is
likely that they represent the repertoire of memory B cells.
In our experiments, we analysed the Ab repertoire formed
by B cells isolated from the peripheral blood of a donor in
June 2004. Therefore, the clones classified into groups 20–
29 should reflect the Ab repertoire generated by infection
and/or vaccination during the period 1997–2003. The
epitopes mapped by using Sydney/97 and Wyoming/2003
HAs were distributed in all five antigenic sites. On the
other hand, the majority of the clones that were classified
into groups 4–19 recognized the antigenic site C. The
presence of two kinds of memory B cells, relatively short-
lived cells and long-lived cells, may explain the mechanism
for generating such differences. For example, the clones
that neutralized the 1968–1973 strains would not have been
stimulated by Ags after viruses with which they were unable
to react became dominant in the circulation. Despite the
lack of stimulation, these memory B cells remained in the
donor’s body for more than 30 years. Therefore, it appears
J. Okada and others
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time; in the most extreme case, memory B cells could
persist for a lifetime. The donor had the chance to be
infected almost every year by novel influenza viruses that
had drifted away from previous viruses. Therefore, some
pre-existing memory B cells produced Abs that could
neutralize the novel viruses, but others produced Abs that
could not neutralize the novel viruses. It might be possible
that even if B cells become memory cells, their numbers
gradually decrease, and eventually they disappear from the
body without further Ag stimulation. In Okada et al.
(2010), we compared 50 aa of the five antigenic sites of 12
strains whose amino acids were variable during the period
1968–2004. While no mutations were introduced into site
C between 1977 and 1993, many mutations were
introduced into sites A and B. According to this hypothesis
the stability of the epitopes would greatly affect the fate of
memory B cells.
Another situation should also be considered to gain insight
into memory B cells. When the donor was infected with
novel viruses, the generation of new B cells and the
activation of pre-existing memory B cells occurred
simultaneously. New amino acids were always found at
several residues in a newly emergent strain with the
exception of the 1970 strain (see Fig. 5 in Okada et al.,
2010). When the amino acid sequences were compared
between the 1970 and 1973 strains, different amino acids
were found at seven residues in the five antigenic sites.
However, there were no clones that neutralized the 1973
strain but did not neutralize the 1968 and 1970 strains. It is
possible that such clones were generated by infection with
the 1973 virus but they did not become long-lived memory
B cells. Thus, we speculate that the fate of newly generated
B cells is determined by whether Abs produced by pre-
existing memory B cells are able to neutralize the newly
emergent viruses. As long as the pre-existing memory B
cells produce neutralizing Abs effective against novel
viruses, it might be difficult for newly generated B cells
against the novel viruses to become long-lived memory
cells. The majority of the clones were classified into three
groups with distinct strain specificity, 1968–1973, 1977–
1993 and 1997–2003; we suspect that this is because the
largest change in antigenic epitopes was observed between
Fig. 5. Comparison of the sites assigned by the EMAC method with those determined by the isolation of escape mutants. (a)
Amino acid sequences of Wyoming/03 HA, those replaced in the chimaeric HA and those in the escape mutants are indicated.
Bars indicate the same amino acid as those of Wyo/03. (b) Locations of the epitopes identified by the EMAC method and by the
isolation of escape mutants are indicated in the 3D structure of HA. The illustrations were constructed by using the structure of
H3 HA [Protein Data Bank (PDB) accession code 1HA0] according to molecular graphics viewer RasMol 2.7.5. Amino acids
indicated in various colours correspond to those used in (a).
Fig. 4. Summary of FCM analyses of 98 mAbs that bound to HA and showed neutralizing activity. Plus (+) indicates that the Ab
reacted with HA expressed on the cell surface. Minus (”) indicates that the Ab did not react with the HA expressed on the cell
surface at all. Blanks indicate that the analysis was not performed. Recognized site: the location of the epitope recognized by
respective clones. (a) The first set of clones, (b) the second set and (c) the third set.
J. Okada and others
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produced by pre-existing B cells could not effectively
neutralize the viruses that were newly emergent between
1973 and 1977 as well as between 1993 and 1997. Although
there could be other possible explanations, an analysis of
another Ab library from a donor who was born in 1944
gave essentially the same results as those described in this
paper (unpublished results).
According to these hypotheses, the reason why memory B
cells producing Abs that recognized site C became
dominant during 1977 and 1993 could be explained as
follows. When amino acid sequences were compared
between the 1973 and 1977 strains, different amino acids
were found at 15 residues in the seven antigenic sites (in
this case, B1 and B2 as well as C1 and C2 were counted as
different sites). Therefore, it was possible that most of the
Abs produced by pre-existing B cells were not effective
against the newly emergent viruses. Then, many kinds of B
cells that produced neutralizing Abs against the emergent
viruses were generated by infection and played roles in
protection against the viruses. Since various sites should
have been immunogenic, the epitopes recognized by such
Abs were located not only at site C but also at sites A and B.
Initially, all of these B cells had equal chances of becoming
long-lived memory B cells. However, while mutations were
introduced into various residues in sites A, B1 and B2
during 1977–1993, no difference was generated in sites C1
and C2. Therefore, the memory B cells that produced Abs
against sites C1 and C2 were stimulated every year by
infection. On the other hand, the growth of B cells
producing Abs that bound to site A or B was not enhanced
after the introduction of mutations into the relevant
residues, and the numbers of these B cells gradually
decreased.
In the present analysis, a set of Abs recognizing site C
played major roles in protection of a donor against the
influenza virus for around 20 years. Since we have analysed
B cells from only two donors to date, it is premature to
generalize our observations to humans. Recently, however,
several papers reported the presence of a neutralizing
epitope that was commonly found among the H1 and H5
strains (Ekiert et al., 2009; Kashyap et al., 2008; Sui et al.,
2009; Throsby et al., 2008). If the epitope whose sequence
has been highly conserved is generally immunogenic in
humans, it might be possible and desirable to develop a
new type of vaccine that can specifically stimulate the
growth of B cells that produce Abs against such a
neutralizing epitope. We also found that Abs recognizing
site C do not show HI activity. Traditionally, the global
influenza surveillance network has adopted the HI assay for
characterization of the antigenic properties of influenza
viruses. Since we could not isolate escape mutants under
the presence of any of the mAbs that recognize site C
(unpublished results), it is possible that the alteration of
sequences in site C is a much rarer event than that of sites
A and B. Thus, we suggest that when the antigenic and
genetic evolution of influenza viruses is examined, the
Fig. 6. The antigenic site of HA recognized by 98 mAbs that
showed binding and neutralizing activity against H3 influenza
viruses. Illustrations of the 3D model were constructed in the same
way as described in Fig. 5(b). The amino acids that formed a
receptor-binding site are marked in grey. When loss of Ab binding
was observed in some chimaeric HA, the amino acids replaced in
the chimaera were marked in the same way as in Fig. 1(b).
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considered (Koelle et al., 2006; Smith et al., 2004).
METHODS
Viruses. Twelve influenza A vaccine strains of type H3N2 (A/Aichi/2/
68, A/Fukuoka/1/70, A/Tokyo/6/73, A/Yamanashi/2/77, A/Niigata/
102/81, A/Fukuoka/C29/85, A/Guizhou/54/89, A/Kita-kyushu/159/93,
A/Sydney/5/97, A/Panama/2007/99, A/Wyoming/3/2003 and A/New
York/55/2004) were used in this study.
Preparation of mAbs. The human mAbs with neutralizing activity
used in this study were described previously (Okada et al., 2010). The
Fab-PP (P denotes a single Fc-binding domain of protein A) form of
Abs (Ito & Kurosawa, 1993) was purified with IgG Sepharose (GE
Healthcare) and used in FCM analysis as well as in the HI assay. Alexa
488-anti-human IgG and Alexa 488-anti-mouse IgG used as the
second Abs in FCM were purchased from Invitrogen. IgG was
prepared by using a high expression vector (Bebbington et al., 1992)
and purified with Protein A Sepharose (GE Healthcare). Purified IgGs
were used in the HI assay.
Construction of plasmid DNAs for cell-surface expression of
HA and chimaeric HAs. Details are described in Supplementary Fig.
S1 and the Supplementary Methods (available in JGV Online).
Cell culture and transfection. 293T cells were maintained in
Dulbecco’smodified Eagle’smedium(Wako) containing 10% FBS and
penicillin/streptomycin (Gibco). For FCM analysis, 293T cells in a
150 mm dish were transfected with 30 mg plasmid DNA (HA-chimaera
expression vector) and 75 ml Lipofectamine LTX (Invitrogen) and were
assayed 24 h after transfection. Cell-surface HA expression was verified
by using anti-HA Ab F49 (Ueda et al., 1998).
Haemadsorption assay. Haemadsorption activity of HA expressed
on the cell surface was checked as described previously Nakajima et al.
(2005) with some modifications. In brief, 0.3 ml of 2% guinea-pig
red blood cells was mixed with 0.3 ml of HA-expressed 293T cell
suspension (5610
5) in a microtube, and the mixture was rotated
slowly at 4 uC. After 1 h, the microtube was allowed to stand for 10–
15 min, so that 293T cells were precipitated at the bottom of the
microtube while almost all of the free blood cells remained
suspended. The suspended blood cells were removed, and the cell
pellet was suspended in 1 ml of PBS in 0.05% NaN3. The microtube
was allowed to stand for 10–15 min and the suspended blood cells
were removed again. The resulting cell pellet was suspended in 40 ml
of PBS in 0.05% NaN3, and the complexes of the HA-expressed 293T
cells and the blood cells were observed under an optical microscope.
FCM analysis. Cells transfected with HA expression vector (5610
5
cells per well) were incubated with 2.5% goat serum in 2.5% BSA for
30 min, then incubated with 5 mg Fab-PP ml
21 or a 1:200 dilution of
mouse mAb F49 for 1 h. Cells were washed with 2.5% BSA, followed
by incubation with Alexa 488-conjugated anti-human IgG or Alexa
488-conjugated anti-mouse IgG for 1 h. Then, cells were washed with
2.5% BSA twice and resuspended in PBS at 5610
5 cells ml
21 for
analysis on a FACScan flow cytometer (Cytomics FC 500; Beckman
Coulter). HR1-007, a haemorrhagic factor of Habu venom that
recognizes the Fab region of the Ab, was used as a negative control for
Fab-PP, and a 1:200 dilution of mouse serum was used as a negative
control for F49. All reactions were performed on ice.
HI assay. The HI test was performed as described previously (Okuno
et al., 1990). Briefly, serial dilutions of 100 mg purified Fab-PP ml
21
or 100 mg purified IgG ml
21 in PBS were prepared. Serial dilutions of
Fab-PP were preincubated with 4 HA units of virus per well. Guinea-
pig red blood cells were added to a final concentration of 0.5%, and
the plate was incubated at room temperature for 30–60 min.
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